Clinical trial · Interventional
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
Role of Radiotherapy to the Primary Lesion in Metastatic Non-small Cell Lung Cancer Patients After First Line Systemic Therapy
NCT04776083CI-TRIAL-00080796completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
| Radiation Therapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3D radiotherapy or IMRT | Radiation | — | UNRESOLVED |
| first line systemic therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- radiotherapy arm
- description
- after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions
- interventionNames
- Drug: first line systemic therapy
- Radiation: 3D radiotherapy or IMRT
- type
- ACTIVE_COMPARATOR
- label
- no intervention arm
- description
- after first line systemic therapy, patients will be kept under follow up
- interventionNames
- Drug: first line systemic therapy
Primary outcomes (2)
- measure
- progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed histological diagnosis of NSCLC. 2. Stage IV disease. 3. Patients with P.S ≤ 2. 4. finished at least 4 cycles of platinum-based doublet chemotherapy if patient has no diver mutation, or at least 3 months of anti-EGFR, Anti-ALK according to their driver mutation with SD, PR or CR. Exclusion Criteria: 1. History of prior irradiation to the lung. 2. residual Malignant pleural or pericardial effusion at randomization time. 3. History of prior malignant tumor likely to interfere with the treatment protocol. 4. Severe comorbidities as measured by morbidity index. 5. Disease progression on first line systemic therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.